A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

This study tests TI-0032-III, a new type of cell-based injection therapy (using engineered immune cells that target a protein called CD19) in adults with relapsed or refractory autoimmune diseases — specifically lupus (SLE), Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis — that have not responded to standard treatments. **You may be eligible if...** - You are 18 to 65 years old - You have one of the qualifying autoimmune diseases (lupus, Sjögren's, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis) - Your disease is moderate to severely active despite prior treatment with standard medications including steroids, immunosuppressants, and biologic drugs - Your CD19 protein levels on B cells are positive by lab testing - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You received an RNA-lipid nanoparticle product within the past 2 years - You have received intravenous immunoglobulin (IVIG) within the past 24 weeks - You have active epilepsy or use certain sedative/psychotropic medications - You have active or poorly controlled infections, including HIV or hepatitis - You have a history of cancer - You are pregnant, breastfeeding, or unable to use effective contraception for 12 months after the last dose Talk to your doctor to see if this trial is right for you.